BUDGT PLANNING AND THE UNPREDICTABILITY OF RARE DISEASES

Abstract

The present study will emphasize the costing of rare diseases within the scope of the Unified Health System (SUS) and the quantitative unpredictability of new carriers, generating budgetary impact on public funds. The survey is merely exploratory, addressing the containment of excess expenses. Thus, it is evidenced that the numerous successful lawsuits imposing on the executive branch the coverage of treatment will lead to the reallocation of funds, thus generating the necessity of budget planning for these unpredictable expenses. Furthermore, many consider health as one of the absolute fundamental rights; however, although indispensable to human condition, not even a fundamental right is absolute, not even life itself, as its relativization may occur in favor of transindividual rights or impossibility of funding. On the other hand, increasing the production of medications nationally would reduce the high cost of treating rare diseases; however, the implementation of new technologies and inputs in the country requires approval from CONITEC (National Commission for the Incorporation of Technologies in the Unified Health System), undergoing considerations and consequently delays in the implementation of new therapies.